Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of "Buy" by Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have been given an average recommendation of "Buy" by the ten analysts that are covering the company, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $40.38.

ORKA has been the subject of several recent research reports. BTIG Research began coverage on shares of Oruka Therapeutics in a report on Thursday, May 22nd. They set a "buy" rating for the company. Wedbush reaffirmed an "outperform" rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, May 15th. Finally, Wall Street Zen cut Oruka Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th.

Institutional Investors Weigh In On Oruka Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ORKA. JPMorgan Chase & Co. purchased a new stake in Oruka Therapeutics during the 4th quarter valued at $54,000. AlphaQuest LLC purchased a new position in shares of Oruka Therapeutics in the first quarter worth $168,000. Cannon Global Investment Management LLC bought a new position in shares of Oruka Therapeutics during the first quarter valued at $195,000. Squarepoint Ops LLC purchased a new stake in shares of Oruka Therapeutics during the fourth quarter valued at $236,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Oruka Therapeutics during the fourth quarter valued at $303,000. Institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Trading Up 0.1%

Shares of ORKA stock opened at $11.98 on Friday. The company's fifty day moving average price is $10.68 and its 200-day moving average price is $12.88. The stock has a market cap of $448.53 million, a PE ratio of -2.66 and a beta of -0.38. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. On average, sell-side analysts forecast that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.